US FDA approves Insmed's lung disease drug
I'm PortAI, I can summarize articles.
The U.S. FDA has approved Insmed's oral drug, Brinsupri, for treating non-cystic fibrosis bronchiectasis, marking it as the first treatment for this chronic lung disease. This condition affects 350,000 to 500,000 adults in the U.S. Brinsupri functions by inhibiting inflammatory enzymes in white blood cells, reducing lung damage caused by overactive immune responses.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments